Saturday , November 25 2017
Home / Resources / Featured Writers / Preliminary results Gymnemosupium II

Preliminary results Gymnemosupium II

Efficacy of the diabetic supplement Gymnemosupium II, a combination of the extracts of Gymnema sylvestre, Pterocarpus marsupium, Diachrome and Vanadium administered to patients with Type 2 diabetes.

Original Materials and Methods

Each capsule of Gymnemosupium II is a proprietary formulation of Gymnema sylvestre, 75% standardized extract, Pterocarpus marsupium, 5% standardized extract, Diachrome, a combination of chromium picolinate and biotin, and vanadium in the form of bis-glycinate oxo vanadium (BVOG).

Each Type II diabetic will receive a total of 8 capsules of Gymnemosupium II a day administered in a four dose a day regiment, 2 capsules will be taken immediately before breakfast, lunch, supper and evening snack. The dose of 8 capsules a day will be maintained by doubling a dose if necessary if an individual dose is missed.

Trial will continue for a period of 90 days utilizing a total of 48 Type II diabetic subjects ranging in age between 30 to 60 years old and currently have a hemoglobin A1c>8.0.

Subjects must be free of any type of renal complication and also not be consuming more than 200mcg of chromium or 1mg of vanadium daily. All participants will give written informed consent and continue their normal diet, exercise routine and doses of oral hypoglycemic and insulin. Two weeks prior and throughout the trial daily morning fasting and supper postprandial blood glucose will be monitored.

Hemoglobin A1c will be taken before administration of the Gymnemosupium II and immediately upon the conclusion of the study. Body weight and blood pressure will also be monitored in the beginning and at the close of the trial. All oral hypoglycemic and insulin doses will be recorded as well. Adverse side effects, if any, will be noted.

First Data Results

A total of 18 patients have completed the 90 day study at this time.

For these 18 patients

Beginning A1c Average 8.75—- ranging from 9.7 to 7.8

Ending A1c Average 7.66—- ranging from 8.8 to 6.9

Average A1c improvement 1.08—- ranging from 2.7 to 0.4

In addition 2 patients so far, have reported increased Postprandial readings after product discontinuation due to completion of the study.

We are awaiting further data and will have a complete report in the near future, however early data reports indicate that Gym II is a safe and effective product